UNSPSC 51312612: Nemazoline hydrochloride

This classification denotes a histamine-1 receptor antagonist and alpha-adrenergic agonist C10H11Cl2N3.ClH, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier EX1KDR36JS, chemically known as benzenamine, 2,6-dichloro-4-((4,5-dihydro-1h-imidazol-2-yl)methyl)-, monohydrochloride, but more generally known as nemazoline hydrochloride, which bears US NIH Compound Identifier 60468. Most nations, for tariff and trade purposes, schedule nemazoline hydrochloride under HS 29332990 and SITC 51573.

As of Q4 2014, NEMAZOLINE HYDROCHLORIDE remains US FDA's Preferred Term for this commodity. Nemazoline hydrochloride bears US NLM identifiers UMLS ID C0632201 and NCI Concept Code C83998. SMILES: C1C(CC(C(C1CL)N)CL)CC2=NCCN2.CL.

UNSPSC 51312612 Nemazoline hydrochloride is a Commodity code that sees minimal recent state and local procurement activity aligned with its nominal scope. The three opportunities posted in the source block—covering naloxone and drug deactivation systems, direct-to-manufacturer prescription programs, and generic multi-source pharmaceuticals and OTC products through cooperative purchasing—do not reflect procurement of nemazoline hydrochloride specifically. State and local issuing bodies appear to be sourcing pharmaceutical products and health-related supplies through broader solicitations tagged to higher-level UNSPSC families or classes rather than this specific commodity code, suggesting either minimal demand for nemazoline hydrochloride as a discrete line item or taxonomic misalignment in how opportunities are being categorized.

The recent opportunities that do appear span issuing bodies including Seminole County, Florida (an IFB for naloxone and drug deactivation systems due July 26, 2023); the Texas Health and Human Services Commission (an RFI on direct-to-manufacturer prescriptions, posted April 3, 2026); and the Minnesota Multistate Cooperative Purchasing Alliance (an RFP for generic pharmaceuticals and OTC products due March 26, 2026). Geographic activity centers on Florida, Texas, and Minnesota with multi-state cooperative reach. The code warrants monitoring rather than active pursuit at present—the source documents no direct solicitations for nemazoline hydrochloride, and the taxonomy mismatch suggests that state and local buyers are addressing their pharmaceutical and medical-supply needs through family-level or class-level codes that capture wider product baskets rather than single-molecule commodities.